# Nudge-based patient education by pharmacists to promote self-care behaviors for preventing and mitigating chemotherapy-induced skin toxicity: rationale, design, and study protocol of the PHARM-NUDGE trial

**Authors:** Yuka Ito, Koji Suzuki, Masahiro Hatori, Takahiko Yagi, Yasunori Miyamoto, Hikaru Sato, Shuichi Watabe, Naoki Shibata, Yume Otsuka, Tatsuya Yagi, Junichi Kawakami

PMC · DOI: 10.1186/s40780-026-00556-4 · 2026-02-21

## TL;DR

This study tests if pharmacist-led education using nudge strategies can help cancer patients avoid or reduce skin toxicity from chemotherapy.

## Contribution

The first randomized trial to evaluate nudge-based education by pharmacists for mitigating chemotherapy-induced skin toxicity.

## Key findings

- The PHARM-NUDGE trial is designed to assess the impact of nudge-based education on patients' preventive behaviors.
- Patients receiving nudge-based education will be compared to those receiving standard education for adherence to skincare behaviors.

## Abstract

Nudge strategies are well-established in behavioral economics as effective approaches for promoting desirable behaviors. However, the potential benefits of integrating nudge-based strategies into pharmacist-led patient education have not yet been demonstrated. Here, we present a study protocol for an interventional trial to address this issue.

The PHARM-NUDGE study is a multicenter, randomized, parallel-group, single-blind, controlled trial prospectively designed to evaluate whether nudge-based pharmacist-led education can promote patients’ preventive behaviors against skin toxicities associated with cancer chemotherapy. The key inclusion criteria are as follows: (1) patients who are men or women and aged 18 years or older and (2) patients scheduled to receive a chemotherapy regimen containing capecitabine, liposomal doxorubicin, lenvatinib, cetuximab, or panitumumab in outpatient chemotherapy units or during hospitalization. The enrolled patients are randomly assigned in a 2:1 ratio to the nudge-based education or standard education groups. Pharmacists responsible for patient education utilize special educational tools that incorporate nudge strategies and provide skincare education to patients assigned to the nudge-based education group. Patients assigned to the standard education group receive skincare education with equivalent content but without nudges. The primary endpoint is the proportion of patients in each group who achieve four or more of the five predefined behavioral criteria.

The PHARM-NUDGE study is the first randomized controlled trial to evaluate the potential benefits of integrating nudge strategies into pharmacist-led skincare education for patients undergoing cancer chemotherapy with a high risk of skin toxicity, with patient enrollment initiated on October 15, 2025. Completion of the trial and acquisition of the final results are eagerly anticipated.

This trial was registeredwith the Japan Registry of Clinical Trials (clinical trial number: jRCT1040250089, registration date: September 3, 2025).

The online version contains supplementary material available at 10.1186/s40780-026-00556-4.

## Linked entities

- **Chemicals:** capecitabine (PubChem CID 60953), doxorubicin (PubChem CID 31703), lenvatinib (PubChem CID 9823820)
- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Diseases:** cancer (MESH:D009369), skin toxicities (MESH:D012871)
- **Chemicals:** capecitabine (MESH:D000069287), cetuximab (MESH:D000068818), doxorubicin (MESH:D004317), lenvatinib (MESH:C531958), panitumumab (MESH:D000077544)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13032257/full.md

---
Source: https://tomesphere.com/paper/PMC13032257